NO20033564L - Ny formulering med modifisert frigivningsvirkning - Google Patents

Ny formulering med modifisert frigivningsvirkning

Info

Publication number
NO20033564L
NO20033564L NO20033564A NO20033564A NO20033564L NO 20033564 L NO20033564 L NO 20033564L NO 20033564 A NO20033564 A NO 20033564A NO 20033564 A NO20033564 A NO 20033564A NO 20033564 L NO20033564 L NO 20033564L
Authority
NO
Norway
Prior art keywords
matrix former
modified release
release effect
formulation
unit dosage
Prior art date
Application number
NO20033564A
Other languages
English (en)
Norwegian (no)
Other versions
NO20033564D0 (no
Inventor
Anne Marie Juppo
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0100478A external-priority patent/SE0100478D0/xx
Priority claimed from SE0100477A external-priority patent/SE0100477D0/xx
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20033564D0 publication Critical patent/NO20033564D0/no
Publication of NO20033564L publication Critical patent/NO20033564L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Cosmetics (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20033564A 2001-02-13 2003-08-12 Ny formulering med modifisert frigivningsvirkning NO20033564L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0100478A SE0100478D0 (sv) 2001-02-13 2001-02-13 Novel formulation
SE0100477A SE0100477D0 (sv) 2001-02-13 2001-02-13 Novel formulation
PCT/SE2002/000228 WO2002064121A1 (en) 2001-02-13 2002-02-08 Novel modified released formulation

Publications (2)

Publication Number Publication Date
NO20033564D0 NO20033564D0 (no) 2003-08-12
NO20033564L true NO20033564L (no) 2003-10-02

Family

ID=26655389

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20033564A NO20033564L (no) 2001-02-13 2003-08-12 Ny formulering med modifisert frigivningsvirkning

Country Status (18)

Country Link
US (3) US20040067252A1 (da)
EP (2) EP1368006B1 (da)
JP (2) JP2004518709A (da)
KR (1) KR20040058103A (da)
CN (2) CN1491104A (da)
AT (1) ATE324871T1 (da)
AU (1) AU2002228579B2 (da)
BR (1) BR0206825A (da)
CA (2) CA2434835A1 (da)
DE (1) DE60211130T2 (da)
DK (1) DK1368006T3 (da)
ES (1) ES2261643T3 (da)
IL (1) IL157075A0 (da)
MX (1) MXPA03007092A (da)
NO (1) NO20033564L (da)
NZ (2) NZ526993A (da)
PT (1) PT1368006E (da)
WO (2) WO2002064118A1 (da)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
AU2003220472A1 (en) * 2002-09-28 2004-04-19 Mcneil-Ppc, Inc. Modified release dosage form with two cores
SE0301904D0 (sv) 2003-06-26 2003-06-26 Astrazeneca Ab Novel imidazopyridine compound II with therapeutic effect
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
KR20060118421A (ko) * 2003-08-29 2006-11-23 다이노젠 파마세우티컬스, 인코포레이티드 위장 운동 장애의 치료에 유용한 조성물
WO2005053652A1 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride
EP1701702A1 (en) * 2003-12-04 2006-09-20 Pfizer Products Inc. Spray-congeal process using an extruder for preparing multiparticulate azithromycin compositions containing preferably a poloxamer and a glyceride
ES2600577T3 (es) 2003-12-04 2017-02-09 Bend Research, Inc. Procedimiento de pulverización-solidificación que usa un extrusor para preparar composiciones en multipartículas de fármacos cristalinos
WO2005053639A2 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Controlled release multiparticulates formed with dissolution enhancers
SE0303451D0 (sv) * 2003-12-18 2003-12-18 Astrazeneca Ab New compounds
MY191349A (en) * 2004-08-27 2022-06-17 Bayer Pharmaceuticals Corp New pharmaceutical compositions for the treatment of hyper-proliferative disorders
SI2001445T1 (sl) * 2006-03-16 2015-02-27 Euro-Celtique S.A. Farmacevtski sferoidi
WO2009111648A1 (en) 2008-03-05 2009-09-11 Vicus Therapeutics, Llc Compositions and methods for mucositis and oncology therapies
WO2011000126A1 (zh) * 2009-06-29 2011-01-06 Liu Yu 脂溶性药物组合物、制备方法及其用途
DK2921486T3 (da) 2009-08-07 2017-11-13 American Life Science Pharmaceuticals Inc Sammensætninger og fremgangsmåder til behandling af beta-amyloid-relaterede sygdomme
US20130165880A1 (en) 2010-09-17 2013-06-27 David T. Amos Antimicrobial disposable absorbent articles
WO2012070030A1 (en) * 2010-11-26 2012-05-31 University Of The Witwatersrand, Johannesburg A pharmaceutical composition
US20130149383A1 (en) * 2011-12-12 2013-06-13 Cory Berkland Sustained release particle formulations of guaifenesin
WO2013090452A1 (en) * 2011-12-12 2013-06-20 Orbis Biosciences, Inc. Sustained release particle formulations
US9867809B2 (en) * 2015-06-30 2018-01-16 Kemin Industries, Inc. Encapsulated active ingredients for controlled enteric release
US9889120B2 (en) 2016-01-14 2018-02-13 Vicus Therapeutics, Llc Combination drug therapies for cancer and methods of making and using them
DE102017108054A1 (de) 2017-04-13 2018-10-18 Natura Werk Gebr. Hiller GmbH & Co. KG Essbare Zusammensetzung zur Verdauungsförderung
EP4076527A4 (en) 2020-01-10 2024-05-15 Consynance Therapeutics, Inc. Therapeutic combinations of drugs and methods of using them
WO2023004113A2 (en) 2021-07-22 2023-01-26 The Regents Of The University Of California Compositions and methods for using purified human rna editing enzymes
WO2023184282A1 (en) * 2022-03-30 2023-10-05 Guizhou Sinorda Biomedicine Co., Ltd X842 formulation

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL248553A (da) * 1959-02-18
HU198844B (en) * 1984-06-14 1989-12-28 Sandoz Ag Process for producing new galenic pharmaceutical composition ensuring retarded release of active ingredient
US4629621A (en) * 1984-07-23 1986-12-16 Zetachron, Inc. Erodible matrix for sustained release bioactive composition
US5015479A (en) * 1987-02-02 1991-05-14 Seamus Mulligan Sustained release capsule or tablet formulation comprising a pharmaceutically acceptable dihydropyridine
US4956182A (en) * 1989-03-16 1990-09-11 Bristol-Myers Company Direct compression cholestyramine tablet and solvent-free coating therefor
US5405617A (en) * 1991-11-07 1995-04-11 Mcneil-Ppc, Inc. Aliphatic or fatty acid esters as a solventless carrier for pharmaceuticals
US5281420A (en) * 1992-05-19 1994-01-25 The Procter & Gamble Company Solid dispersion compositions of tebufelone
US5433951A (en) * 1993-10-13 1995-07-18 Bristol-Myers Squibb Company Sustained release formulation containing captopril and method
KR100354702B1 (ko) * 1993-11-23 2002-12-28 유로-셀티크 소시에떼 아노뉨 약학조성물의제조방법및서방형조성물
NZ270439A (en) * 1995-02-02 1996-04-26 Bernard Charles Sherman Solid slow release pharmaceutical composition: carrier is polyethylene glycol and hydrophilic gel-forming polymer
US5851555A (en) * 1997-08-15 1998-12-22 Fuisz Technologies Ltd. Controlled release dosage forms containing water soluble drugs
SE9801526D0 (sv) * 1998-04-29 1998-04-29 Astra Ab New compounds
US8293277B2 (en) * 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions

Also Published As

Publication number Publication date
MXPA03007092A (es) 2003-11-18
ATE324871T1 (de) 2006-06-15
NO20033564D0 (no) 2003-08-12
EP1368006A1 (en) 2003-12-10
NZ526993A (en) 2005-01-28
CA2434542A1 (en) 2002-08-22
HK1059740A1 (en) 2004-07-16
IL157075A0 (en) 2004-02-08
US20040067252A1 (en) 2004-04-08
US20040067256A1 (en) 2004-04-08
NZ526994A (en) 2005-01-28
JP2004518709A (ja) 2004-06-24
EP1361868A1 (en) 2003-11-19
DE60211130T2 (de) 2006-11-30
KR20040058103A (ko) 2004-07-03
CA2434835A1 (en) 2002-08-22
EP1368006B1 (en) 2006-05-03
CN1491105A (zh) 2004-04-21
WO2002064121A1 (en) 2002-08-22
AU2002228579B2 (en) 2006-07-27
DK1368006T3 (da) 2006-07-24
JP2004518708A (ja) 2004-06-24
US20080118560A1 (en) 2008-05-22
ES2261643T3 (es) 2006-11-16
WO2002064118A1 (en) 2002-08-22
PT1368006E (pt) 2006-08-31
DE60211130D1 (de) 2006-06-08
CN1491104A (zh) 2004-04-21
BR0206825A (pt) 2004-02-25

Similar Documents

Publication Publication Date Title
NO20033564D0 (no) Ny formulering med modifisert frigivningsvirkning
JP6875407B2 (ja) Ｊａｋキナーゼ阻害剤またはその薬剤的に許容される塩を含有する医薬組成物
US6531153B2 (en) Composition with sustained release of levodopa and carbidopa
HUP0100469A2 (hu) Eljárás harapással diszpergálható tabletták előállítására
EP0378255A3 (en) 2-aminopyrimidinone derivatives
BRPI0015567B8 (pt) composto, composição farmacêutica, forma de unidade de dosagem, uso da composição farmacêutica e método para preparar uma composição farmacêutica
KR960700070A (ko) 백신 제제(vaccine preparations)
MX2010008711A (es) Composiciones farmaceuticas de entacapona, levopoda y carbidopa, con biodisponibilidad mejorada.
NO20000466D0 (no) Farmasoeytisk preparat for sure, lipofile forbindelser i form av en selvemulgerende formulering
EE04700B1 (et) Segamisest sõltumatud toimeainet aeglustatult vabastavad mitmeosalised ravimvormid ja nende valmistamismeetodid
US20050147659A1 (en) Pharmaceutical composition comprising an oil/water/oil double microemulsion incorporated into a solid support
JP2018527291A (ja) 駆虫薬の大環状ラクトンを含むミクロスフェア
KR20110115592A (ko) 피리도피리미디논의 고체 경구 제제
KR102861006B1 (ko) 분산성 조성물
DE60233552D1 (de) Fenofibrattabletten
WO2007061415A1 (en) Pharmaceutical compositions of telmisartan
IL99237A (en) Preparation of a tablet or dragee composition containing a moisture-heat- and light-sensitive compounds having monoclinic crystalline structure
MX2011004572A (es) Formulaciones de liberacion prolongada que comprenden un derivado de 2-oxo-1-pirrolidina.
WO2005041876A3 (en) Spill resistant formulations containing clays
JPH0617304B2 (ja) 制癌剤
BRPI0307319B8 (pt) forma de dosagem oral para liberação controlada de droga e processo para sua preparação
CS277291A3 (en) Pharmaceutical
CA2520813A1 (en) Sustained release formulations of alkylene dioxybenzene derivatives useful as 5-ht1a agonists
JP2936574B2 (ja) 鎮痛剤
HUP0301334A2 (hu) Szubsztituált akriloil-disztamicin-származékokat és taxánokat és/vagy antimetabolitokat tartalmazó kombinált tumorellenes kompozíciók

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application